Medicare Enrolled
Dr. Stanley Schinke, M.D.
Optician · Hemet, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Schinke from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Schinke?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Schinke
Dr. Stanley Schinke is an optician specialist in Hemet, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Schinke performed 251,451 Medicare services across 3,914 unique beneficiaries.
Between the years covered by Open Payments, Dr. Schinke received a total of $19,967 from 92 pharmaceutical and/or device companies across 945 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Schinke is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in CA
$19,967 industry payments
Medicare Practice Summary
Medicare Utilization ↗251,451
Medicare services
Top 0% in CA for optician
3,914
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~12,573 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
92,250 | $1 | $2 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
18,360 | $37 | $62 |
| Azacitidine chemotherapy injection An injection of the medication azacitidine, measured at 1 mg per unit. |
18,000 | $0 | $3 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
14,890 | $6 | $14 |
| Nivolumab injection (Opdivo) | 10,780 | $24 | $32 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
10,710 | $0 | $1 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
9,600 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 8,820 | $17 | $22 |
| Pembrolizumab injection (Keytruda) | 8,200 | $43 | $58 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 7,951 | $0 | $0 |
| Injection, immune globulin (bivigam), 500 mg | 6,520 | $56 | $80 |
| Eflapegrastim injection, 0.1 mg An injection of eflapegrastim-xnst administered at a dose of 0.1 mg. |
6,336 | $26 | $41 |
| Paclitaxel chemotherapy injection | 5,484 | $0 | $1 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
5,392 | $4 | $55 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,890 | $6 | $15 |
| Anti-nausea injection (aprepitant) | 2,990 | $1 | $4 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,629 | $0 | $0 |
| Injection, granisetron, extended-release, 0.1 mg | 2,600 | $5 | $7 |
| Rituximab-arrx biosimilar injection, 10 mg An injection of rituximab-arrx, a biosimilar medication, administered in a 10 mg dose. |
2,400 | $35 | $95 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,545 | $8 | $11 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,522 | $96 | $131 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,420 | $1 | $13 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,134 | $3 | $3 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
947 | $12 | $15 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
880 | $13 | $16 |
| Injection, leucovorin calcium, per 50 mg | 626 | $3 | $13 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
411 | $111 | $139 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
341 | $59 | $77 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
319 | $55 | $69 |
| Pegfilgrastim-fpgk biosimilar injection, 0.5 mg An injection of pegfilgrastim-fpgk, a biosimilar medication, administered at a dose of 0.5 mg. |
300 | $274 | $384 |
| Unclassified biologic A biologic product that does not have a specific HCPCS code assigned. |
280 | $265 | $386 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
266 | $2 | $7 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
259 | $1 | $2 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
247 | $1 | $5 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
229 | $17 | $21 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
215 | $2 | $7 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
213 | $6 | $11 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
158 | $22 | $29 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
136 | $3 | $8 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
135 | $55 | $68 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
121 | $24 | $30 |
| New patient office visit, complex (60-74 min) | 113 | $170 | $225 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
98 | $63 | $80 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
80 | $61 | $175 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
76 | $142 | $184 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
74 | $24 | $30 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
66 | $29 | $36 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 59 | $11 | $14 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
58 | $22 | $28 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
49 | $75 | $104 |
| Injection, alteplase recombinant, 1 mg | 42 | $68 | $101 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 39 | $329 | $618 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
35 | $135 | $176 |
| Refilling and maintenance of portable pump This service involves refilling and performing maintenance on a portable pump. |
32 | $107 | $135 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
32 | $1 | $1 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
29 | $30 | $39 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
23 | $17 | $21 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $105 | $131 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
19 | $47 | $59 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
41.4% high complexity
56.5% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,967
Total received (2018-2024)
Avg $2,852/year across 7 years
Top 9% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
92
Companies
945
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,043 (95.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$757 (3.8%)
Other
Charitable contributions, space rental, and other categories
$167 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,478
2023
$3,376
2022
$3,427
2021
$2,169
2020
$1,100
2019
$3,481
2018
$2,936
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$469
Merck Sharp & Dohme LLC
$245
E.R. Squibb & Sons, L.L.C.
$195
Daiichi Sankyo Inc.
$193
ABBVIE INC.
$188
Janssen Biotech, Inc.
$182
PFIZER INC.
$173
AstraZeneca Pharmaceuticals LP
$167
Eisai Inc.
$137
Takeda Pharmaceuticals U.S.A., Inc.
$129
Astellas Pharma US Inc
$116
GENZYME CORPORATION
$80
ARRAY BIOPHARMA INC
$79
Genentech USA, Inc.
$72
Karyopharm Therapeutics Inc.
$69
Gilead Sciences, Inc.
$65
PUMA BIOTECHNOLOGY, INC.
$64
Dendreon Pharmaceuticals LLC
$59
BeiGene USA, Inc.
$55
Lilly USA, LLC
$55
Exelixis Inc.
$55
Alexion Pharmaceuticals, Inc.
$53
Regeneron Healthcare Solutions, Inc.
$52
Pharmacosmos Therapeutics Inc.
$51
JAZZ PHARMACEUTICALS INC.
$50
Mirati Therapeutics, Inc.
$47
SpringWorks Therapeutics, Inc.
$45
EMD Serono, Inc.
$38
Octapharma USA, Inc.
$35
Immunocore Limited
$33
Celgene Corporation
$30
Rigel Pharmaceuticals, Inc.
$29
Blueprint Medicines Corporation
$28
MorphoSys, US Inc.
$25
Stemline Therapeutics Inc.
$22
Ipsen Biopharmaceuticals, Inc
$21
GlaxoSmithKline, LLC.
$18
Incyte Corporation
$18
Acrotech Biopharma Inc.
$18
Kite Pharma, Inc.
$16
Top 3 companies account for 26.1% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,712
Novartis Pharmaceuticals Corporation
$1,665
AstraZeneca Pharmaceuticals LP
$1,388
E.R. Squibb & Sons, L.L.C.
$1,166
PFIZER INC.
$945
Merck Sharp & Dohme LLC
$767
Amgen Inc.
$639
Takeda Pharmaceuticals U.S.A., Inc.
$531
Astellas Pharma US Inc
$531
Merck Sharp & Dohme Corporation
$507
Genentech USA, Inc.
$497
Seagen Inc.
$489
NOVARTIS PHARMACEUTICALS CORPORATION
$419
Celgene Corporation
$389
Daiichi Sankyo Inc.
$377
Teva Pharmaceuticals USA, Inc.
$375
GENZYME CORPORATION
$344
Eisai Inc.
$332
Alexion Pharmaceuticals, Inc.
$313
Gilead Sciences, Inc.
$297
Incyte Corporation
$297
Karyopharm Therapeutics Inc.
$287
Seattle Genetics, Inc.
$286
Lilly USA, LLC
$243
GlaxoSmithKline, LLC.
$210
ABBVIE INC.
$207
Blueprint Medicines Corporation
$186
EMD Serono, Inc.
$185
Bayer HealthCare Pharmaceuticals Inc.
$185
Coherus Biosciences Inc.
$184
Pharmacyclics LLC, An AbbVie Company
$157
Stemline Therapeutics Inc.
$149
BeiGene USA, Inc.
$147
Rigel Pharmaceuticals, Inc.
$146
Puma Biotechnology, Inc.
$141
Pharmacyclics LLC, an AbbVie Company
$132
ARRAY BIOPHARMA INC
$130
Regeneron Healthcare Solutions, Inc.
$129
Exelixis Inc.
$129
Verastem, Inc.
$127
Ipsen Biopharmaceuticals, Inc
$124
Dendreon Pharmaceuticals LLC
$121
Foundation Medicine, Inc.
$110
AbbVie, Inc.
$106
Pharmacosmos Therapeutics Inc.
$103
Adaptive Biotechnologies Corporation
$93
Kite Pharma, Inc.
$87
Mirati Therapeutics, Inc.
$85
PUMA BIOTECHNOLOGY, INC.
$84
EISAI INC.
$82
JAZZ PHARMACEUTICALS INC.
$82
Helsinn Therapeutics (U.S.), Inc.
$77
Myovant Sciences Inc.
$69
Mylan Institutional Inc.
$69
Bayer Healthcare Pharmaceuticals Inc.
$69
Deciphera Pharmaceuticals Inc.
$67
Boehringer Ingelheim Pharmaceuticals, Inc.
$65
AMAG Pharmaceuticals, Inc.
$62
Taiho Oncology, Inc.
$60
Clovis Oncology, Inc.
$59
AVEO Pharmaceuticals, Inc.
$55
Janssen Pharmaceuticals, Inc
$50
CSL Behring
$48
SpringWorks Therapeutics, Inc.
$45
Sobi, Inc
$45
Verity Pharmaceuticals Inc.
$45
TerSera Therapeutics LLC
$44
Otsuka America Pharmaceutical, Inc.
$37
Spectrum Pharmaceuticals Inc.
$36
Octapharma USA, Inc.
$35
TESARO, Inc.
$35
Kyowa Kirin, Inc.
$34
Myriad Genetic Laboratories, Inc.
$34
Immunocore Limited
$33
Partner Therapeutics, Inc.
$30
Telix Pharmaceuticals
$28
Aveo Pharmaceuticals, Inc.
$27
MorphoSys, US Inc.
$25
Epizyme, Inc.,
$24
Grifols USA, LLC
$23
AbbVie Inc.
$20
Dova Pharmaceuticals
$20
Secura Bio, Inc.
$20
SERVIER PHARMACEUTICALS LLC
$20
INSYS Therapeutics Inc
$19
Organon LLC
$19
Medtronic USA, Inc.
$18
West Therapeutics Development, LLC
$18
Acrotech Biopharma Inc.
$18
APTEVO THERAPEUTICS INC
$17
BTG International, Inc.
$17
MAYNE PHARMA INC.
$13
Top 3 companies account for 23.9% of all-time payments
Associated products mentioned in payments ›
ABILIFY · ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AVYCAZ · AYVAKIT · Abraxane · Alecensa · Aliqopa · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRACAnalysis CDx · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · CEREZYME · CHANTIX · COSELA · CROFAB · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Enhertu · Erleada · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · Folotyn · Fulphila · GAZYVA · GILOTRIF · Haegarda · Halaven · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · IXINITY · Idelvion · Imbruvica · Itovebi · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · KYPHON Balloon Kyphoplasty · Kyprolis · LEUKINE · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lazanda · Lenvima · Leukine · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SUBSYS · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tazverik · Thrombate III · Tibsovo · Trelstar · Trodelvy · Truxima · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VELCADE · VENCLEXTA · VERZENIO · Vanflyta · Vectibix · Venclexta · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xtandi · YERVOY · Yescarta · ZEJULA · ZEPZELCA · ZYKADIA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 9% for optician in CA.
Geographic Context
Opticians within 10 mi
88
Per 100K population
3.6
County median income
$89,672
Nearest hospital
HEMET GLOBAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Schinke is a mixed practice specialist, with above-average Medicare volume (top 0% in CA), with low-engagement industry engagement in the top 9% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Schinke experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Schinke performed 92,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Schinke receive payments from pharmaceutical companies?
Yes. Dr. Schinke received a total of $19,967 from 92 companies across 945 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Schinke's costs compare to other opticians in Hemet?
Dr. Schinke's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Schinke) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Hemet
Browse opticians in Hemet ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology